Xenon Pharmaceuticals Total Assets 2012-2022 | XENE
Xenon Pharmaceuticals total assets from 2012 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Xenon Pharmaceuticals Annual Total Assets
(Millions of US $) |
| 2021 |
$572 |
| 2020 |
$189 |
| 2019 |
$148 |
| 2018 |
$122 |
| 2017 |
$46 |
| 2016 |
$67 |
| 2015 |
$64 |
| 2014 |
$87 |
| 2013 |
$54 |
| 2012 |
$63 |
| 2011 |
$0 |
Xenon Pharmaceuticals Quarterly Total Assets
(Millions of US $) |
| 2022-03-31 |
$558 |
| 2021-12-31 |
$572 |
| 2021-09-30 |
$264 |
| 2021-06-30 |
$275 |
| 2021-03-31 |
$291 |
| 2020-12-31 |
$189 |
| 2020-09-30 |
$199 |
| 2020-06-30 |
$211 |
| 2020-03-31 |
$237 |
| 2019-12-31 |
$148 |
| 2019-09-30 |
$99 |
| 2019-06-30 |
$106 |
| 2019-03-31 |
$115 |
| 2018-12-31 |
$122 |
| 2018-09-30 |
$130 |
| 2018-06-30 |
$65 |
| 2018-03-31 |
$38 |
| 2017-12-31 |
$46 |
| 2017-09-30 |
$46 |
| 2017-06-30 |
$54 |
| 2017-03-31 |
$61 |
| 2016-12-31 |
$67 |
| 2016-09-30 |
$73 |
| 2016-06-30 |
$56 |
| 2016-03-31 |
$61 |
| 2015-12-31 |
$64 |
| 2015-09-30 |
$70 |
| 2015-06-30 |
$77 |
| 2015-03-31 |
$79 |
| 2014-12-31 |
$87 |
| 2014-09-30 |
$54 |
| 2014-06-30 |
$0 |
| 2014-03-31 |
$0 |
| 2013-12-31 |
$0 |
| 2013-09-30 |
$0 |
| 2012-12-31 |
$63 |
| 2011-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.581B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
